Neurocrine Biosciences (NBIX) said it has obtained exclusive rights for all indications to develop and commercialize osavampator for patients with inadequate response to treatment of major depressive disorder following an amended agreement with Takeda Pharmaceuticals.
The rights are for all territories worldwide, except Japan, where Takeda will reacquire exclusive rights, according to a statement late Monday. Each company is responsible for development costs in their respective region, and both companies are eligible to receive royalty payments.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.